Daiwa Securities Group Inc. Acquires 973 Shares of Insulet Co. (NASDAQ:PODD)

Daiwa Securities Group Inc. grew its stake in Insulet Co. (NASDAQ:PODD) by 8.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,378 shares of the medical instruments supplier’s stock after purchasing an additional 973 shares during the period. Daiwa Securities Group Inc.’s holdings in Insulet were worth $2,881,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Wedmont Private Capital increased its position in shares of Insulet by 3.5% during the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock worth $326,000 after purchasing an additional 48 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd grew its position in Insulet by 4.7% during the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock worth $250,000 after acquiring an additional 48 shares during the last quarter. Blue Trust Inc. increased its holdings in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Insulet by 1.1% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock worth $1,264,000 after purchasing an additional 66 shares in the last quarter. Finally, Greenleaf Trust grew its holdings in shares of Insulet by 4.2% during the third quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier’s stock worth $415,000 after purchasing an additional 72 shares during the last quarter.

Insulet Trading Up 0.2 %

Shares of NASDAQ PODD opened at $266.92 on Thursday. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.40. The stock has a market cap of $18.72 billion, a price-to-earnings ratio of 45.71, a P/E/G ratio of 4.08 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company’s fifty day moving average is $242.59 and its 200-day moving average is $212.36.

Wall Street Analysts Forecast Growth

PODD has been the topic of several research reports. Canaccord Genuity Group upped their price target on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Barclays upped their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Morgan Stanley upped their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Finally, Piper Sandler boosted their target price on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.